Advertisement
Screener

Ovid Therapeutics Inc. (OVID) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

1.9 / 5 stars · 25/65 Roast Me

Ovid Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

Ovid Therapeutics Inc. (OVID) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 2.37 million shares for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-13.

Discontinued

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2023-03-13

  • Ovid Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2018-03-31 was 16.63K shares, a 88.08% decline year-over-year.
  • Ovid Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2017-12-31 was 22.45K shares.
  • Ovid Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2017-09-30 was 60.97K shares.
  • Ovid Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2017-06-30 was 0.00 shares.
  • Ovid Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 2.37M shares, a 70.92% increase from fiscal 2021.
  • Ovid Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2021 was 1.38M shares, a 233.08% increase from fiscal 2020.
  • Ovid Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2020 was 415.53K shares, a 51.49% decline from fiscal 2019.
  • Ovid Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2019 was 856.60K shares, a 15.13% decline from fiscal 2018.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month
2022-12-312.37M shares
10-K · filed 2023-03-13
2021-12-311.38M shares
10-K · filed 2023-03-13
2020-12-31415.53K shares
10-K · filed 2022-03-15
2019-12-31856.60K shares
10-K · filed 2021-03-15
2018-12-311.01M shares
10-K · filed 2020-03-11
2018-03-3116.63K shares
10-Q · filed 2018-05-08
39.08K shares
derived: sum of 2 quarters · filed 2019-03-07
100.05K shares
derived: sum of 3 quarters · filed 2019-03-07
100.05K shares
derived: sum of 4 quarters · filed 2019-03-07
2017-12-3122.45K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07
83.42K shares
derived: sum of 2 quarters · filed 2019-03-07
83.42K shares
derived: sum of 3 quarters · filed 2019-03-07
222.95K shares
10-K · filed 2019-03-07
2017-09-3060.97K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09
60.97K shares
derived: sum of 2 quarters · filed 2017-11-09
200.50K shares
10-Q · filed 2017-11-09
2017-06-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10
139.53K shares
10-Q · filed 2017-08-10
2017-03-31139.53K shares
10-Q · filed 2017-06-13
2016-12-31260.46K shares
10-K · filed 2018-03-29
2015-12-310.00 shares
10-K · filed 2018-03-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
ASSEMBLY BIOSCIENCES, INC. (ASMB)United States$0.481B-13,053.96
CAPRICOR THERAPEUTICS, INC. (CAPR)United States$0.499B-10.81
PUMA BIOTECHNOLOGY, INC. (PBYI)United States$0.507B15.53
ARVINAS, INC. (ARVN)United States$0.510B58.38
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
Evolus, Inc. (EOLS)United States$0.519B-13.32
CRESCENT BIOPHARMA, INC. (CBIO)United States$0.529B-5.20
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63
Indaptus Therapeutics, Inc. (INDP)United States$0.537B